STEMCELLS INC Form 8-K December 03, 2007

Delaware

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

| Date of Report (Date of Earliest Event Reported): | November 30, 2007 |
|---|-------------------|
|---|-------------------|

# StemCells, Inc.

(Exact name of registrant as specified in its charter)

000-19871

| (State or other jurisdiction  | (Commission                        | (I.R.S. Employer                                     |
|---|------------------------------------|--|
| of incorporation)   | File Number)                       | Identification No.)                                  |
| 3155 Porter Drive, Palo Alto, California  |                                    | 94304  |
| (Address of principal executive offices)  |                                    | (Zip Code)   |
| Registrant s telephone number, including area   | ı code:                            | 650.475.3100   |
|   | Not Applicable                     |  |
| Former name of  | r former address, if changed since | last report  |
|   |                                    |  |
| Check the appropriate box below if the Form 8-K filing is the following provisions:                             | intended to simultaneously satisfy | the filing obligation of the registrant under any of |
| [ ] Written communications pursuant to Rule 425 under [ ] Soliciting material pursuant to Rule 14a-12 under the | •                                  |  |

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

94-3078125

## Edgar Filing: STEMCELLS INC - Form 8-K

#### <u>Top of the Form</u> Item 8.01 Other Events.

On November 30, 2007, StemCells, Inc. announced that the first patient to receive a transplant of HuCNS-SC cells (purified human neural stem cells) in the Company's Phase I clinical trial has completed the trial. The patient, who was transplanted in November 2006, has finished the twelve-month period of immunosuppression and follow-up, and undergone the last of the tests and observations required by the trial protocol. A copy of the press release is attached hereto as Exhibit 99.1.

## Edgar Filing: STEMCELLS INC - Form 8-K

## Top of the Form

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

November 30, 2007 By: Kenneth B. Stratton

Name: Kenneth B. Stratton Title: General Counsel

## Edgar Filing: STEMCELLS INC - Form 8-K

## Top of the Form

### Exhibit Index

| Exhibit No. | Description                           |
|-------------|---------------------------------------|
| 99.1        | Press Release dated November 30, 2007 |